Incentivising antibiotic research and development: is the UK's subscription payment model part of the solution?
Lancet Infect Dis
.
2020 Feb;20(2):162-163.
doi: 10.1016/S1473-3099(19)30701-7.
Authors
Michael Anderson
1
,
Elias Mossialos
2
Affiliations
1
Department of Health Policy, The London School of Economics and Political Science, London WC2A 2AE, UK. Electronic address: m.anderson5@lse.ac.uk.
2
Department of Health Policy, The London School of Economics and Political Science, London WC2A 2AE, UK.
PMID:
32006497
DOI:
10.1016/S1473-3099(19)30701-7
No abstract available
MeSH terms
Anti-Bacterial Agents / economics*
Humans
Marketing / economics
United Kingdom
Substances
Anti-Bacterial Agents